To prepare for competition from generic versions of its cholesterol medicine Lipitor, the world's largest drug maker will outsource more manufacturing and ...
... emerging markets and speed the pace of launching new drugs to offset looming generic competition for its $12 billion-a-year Lipitor cholesterol fighter. ...
... emerging markets and speed the pace of launching new drugs to offset looming generic competition for its $12 billion-a-year Lipitor cholesterol fighter. ...
Chairman and CEO Jeff Kindler spoke at length about the looming patent expiration for Lipitor. He acknowledged the event "is of a different magnitude" and ...
Chairman and CEO Jeff Kindler spoke at length about the looming patent expiration for Lipitor. He acknowledged the event "is of a different magnitude" and ...
The pharmaceutical giant has downsized dramatically ahead of the patent loss for its cholesterol drug Lipitor. By Aaron Smith, CNNMoney.com staff writer ...
The pharmaceutical giant has downsized dramatically ahead of the patent loss for its cholesterol drug Lipitor. By Aaron Smith, CNNMoney.com staff writer ...
The key patent on Lipitor, which had sales of $3.4 billion in the fourth quarter, expires in November 2011. "We are proactively managing our total cost ...
... outsource more drug manufacturing, lower costs ahead of generic competition for its blockbuster cholesterol drug, Lipitor, and expand broadly in China. ...
Chairman and CEO Jeff Kindler spoke at length about the looming patent expiration for Lipitor. He acknowledged the event "is of a different magnitude" and ...